Mabylon AG raised CHF 30M in funding to advance its lead program MY006. The round saw significant investment from former Roche management and board members.

Aug 12, 2025•15 days ago

Amount Raised

CHF30 Million

SchlierenBiotechnology

Investors

Former Management And Board Members Of RochePrivate Investors

Description

Mabylon AG, based in Schlieren, Switzerland, specializes in human-derived antibodies. The company raised CHF 30M to complete a Phase Ia/b trial for its tri-specific antibody MY006. Major backers included former management and board members from Roche. The funds will help generate safety and efficacy data by 2027.

Company Information

Company

Mabylon AG

Location

Schlieren, Zurich, Switzerland

About

Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform rapidly identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends